Mortality in Guillain-Barré syndrome

Neurology

Volumn 80, Issue 18, 2013, Pages 1650-1654

  Van Den Berg, Bianca ^a   Bunschoten, Carina ^a   Van Doorn, Pieter A ^a   Jacobs, Bart C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DISABILITY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; WEAKNESS;

ACUTE DISEASE; ADULT; AGED; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFECTION; INTENSIVE CARE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESPIRATORY INSUFFICIENCY; RISK FACTORS;

EID: 84879089912     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182904fcc     Document Type: Article

References (10)

1. Dhar R, Stitt L, Hahn AF. The morbidity and outcome of patients with Guillain-Barré syndrome admitted to the intensive care unit. J Neurol Sci 2008;264:121-128.
2. Lawn ND, Wijdicks FM. Fatal Guillain-Barré syndrome. Neurology 1999;52:635-638.
3. Winer JB, Hughes RAC, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988;51:605-612.
4. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349:225-230.
5. Italian Guillain-Barré Study Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. Brain 1996;119:2053-2061.
6. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology 2008;70:1608-1613.
7. Ruts L, Drenthen J, Jacobs BC, Van Doorn PA; On behalf of the Dutch Guillain-Barré Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology 2010;74:1680-1686.
8. Van der Meché FGA, Schmitz PIM. Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
9. Van Koningsveld R, Schmitz PIM, Van der Meché FGA, Visser LH, Meulstee J, Van Doorn PA; Dutch Guillain-Barré Study Group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:192-196.
10. Van Koningsveld R, Steyerberg EW, Hughes RAC, Swan AV, Van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007;6:589-594.